Advaxis, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Advaxis, Inc. – Product Pipeline Review – 2016’, provides an overview of the Advaxis, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Advaxis, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Advaxis, Inc.

The report provides overview of Advaxis, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Advaxis, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Advaxis, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Advaxis, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Advaxis, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Advaxis, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Advaxis, Inc. Snapshot 6

Advaxis, Inc. Overview 6

Key Information 6

Key Facts 6

Advaxis, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Advaxis, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Advaxis, Inc. - Pipeline Products Glance 12

Advaxis, Inc. - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Advaxis, Inc. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Advaxis, Inc. - Drug Profiles 15

axalimogene filolisbac 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

ADXS-HER2 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ADXS-PSA 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Adxs-LmddA159 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ADXS-NEO 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ADXS-TNBC 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Lm-LLO-CA9 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Lm-LLO-CD105A 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Lm-LLO-Flk1 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Lm-LLO-HMWMAAC 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Lm-LLO-ISG15 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Lovaxin S 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Vaccine to Target CEA for Ovarian Cancer 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Vaccine to Target FAP for Breast and Colorectal Cancer 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Vaccine to Target HER2 and CA9 for Breast Cancer 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Vaccine to Target Her2 and HMWMAA for Breast Cancer 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Vaccine to Target IL-13R Alpha2 for Solid Tumor 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Vaccine to Target PSA and HMWMAA for Prostate Cancer 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Vaccine to Target PSCA for Prostate Cancer 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Vaccine to Target WT1 for Oncology 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Advaxis, Inc. - Pipeline Analysis 55

Advaxis, Inc. - Pipeline Products by Target 55

Advaxis, Inc. - Pipeline Products by Route of Administration 57

Advaxis, Inc. - Pipeline Products by Molecule Type 58

Advaxis, Inc. - Recent Pipeline Updates 59

Advaxis, Inc. - Dormant Projects 75

Advaxis, Inc. - Company Statement 76

Advaxis, Inc. - Company Statement 76

Advaxis, Inc. - Locations And Subsidiaries 80

Head Office 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 81

Disclaimer 82

List of Tables

List of Tables

Advaxis, Inc., Key Information 6

Advaxis, Inc., Key Facts 6

Advaxis, Inc. – Pipeline by Indication, 2016 8

Advaxis, Inc. – Pipeline by Stage of Development, 2016 10

Advaxis, Inc. – Monotherapy Products in Pipeline, 2016 11

Advaxis, Inc. – Phase II, 2016 12

Advaxis, Inc. – Phase I, 2016 13

Advaxis, Inc. – Preclinical, 2016 14

Advaxis, Inc. – Pipeline by Target, 2016 55

Advaxis, Inc. – Pipeline by Route of Administration, 2016 57

Advaxis, Inc. – Pipeline by Molecule Type, 2016 58

Advaxis, Inc. – Recent Pipeline Updates, 2016 59

Advaxis, Inc. – Dormant Developmental Projects,2016 75

List of Figures

List of Figures

Advaxis, Inc. – Pipeline by Top 10 Indication, 2016 8

Advaxis, Inc. – Pipeline by Stage of Development, 2016 10

Advaxis, Inc. – Monotherapy Products in Pipeline, 2016 11

Advaxis, Inc. – Pipeline by Top 10 Target, 2016 55

Advaxis, Inc. – Pipeline by Route of Administration, 2016 57

Advaxis, Inc. – Pipeline by Molecule Type, 2016 58

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports